TABLE 1.
Baseline Characteristics
| Switchers (n = 466) |
Nonswitchers (n = 7,597) |
Overall (N = 8,063) |
|
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 40.9 (14.3) | 41.3 (14.2) | 41.2 (14.2) |
| Sex, n (%) | |||
| Male | 201 (43.1) | 3,169 (41.7) | 3,370 (41.8) |
| Female | 265 (56.9) | 4,428 (58.3) | 4,693 (58.2) |
| Insurance plan type, n (%) | |||
| Comprehensive | 18 (3.9) | 175 (2.3) | 193 (2.4) |
| EPO or PPO | 206 (44.2) | 3,658 (48.2) | 3,864 (47.9) |
| HMO | 56 (12.0) | 962 (12.7) | 1,018 (12.6) |
| POS | 35 (7.5) | 700 (9.2) | 735 (9.1) |
| CDHP or HDHP | 147 (31.5) | 1,976 (26.0) | 2,123 (26.3) |
| Unknown | 4 (0.9) | 126 (1.7) | 130 (1.6) |
| Geographic region, n (%) | |||
| Northeast | 64 (13.7) | 1,217 (16.0) | 1,281 (15.9) |
| North Central | 86 (18.5) | 1,252 (16.5) | 1,338 (16.6) |
| South | 253 (54.3) | 3,958 (52.1) | 4,211 (52.2) |
| West | 62 (13.3) | 1,138 (15.0) | 1,200 (14.9) |
| Unknown | 1 (0.2) | 32 (0.4) | 33 (0.4) |
| CCI, mean (SD) | 0.5 (0.9) | 0.5 (1.0) | 0.5 (1.0) |
| Atopic comorbidities, n (%) | |||
| Allergic rhinitis | 99 (21.2) | 1,837 (24.2) | 1,936 (24.0) |
| Asthma | 65 (13.9) | 1,447 (19.0) | 1,512 (18.8) |
| Chronic sinusitis | 17 (3.6) | 306 (4.0) | 323 (4.0) |
| Nasal polyps | 19 (4.1) | 285 (3.8) | 304 (3.8) |
| Food allergy | 16 (3.4) | 232 (3.1) | 248 (3.1) |
| Allergic conjunctivitis | 14 (3.0) | 198 (2.6) | 212 (2.6) |
| Atopic keratoconjunctivitis | 7 (1.5) | 97 (1.3) | 104 (1.3) |
| Allergic urticaria | 7 (1.5) | 71 (0.9) | 78 (1.0) |
| Eosinophilic esophagitis | 0 (0) | 51 (0.7) | 51 (0.6) |
| Indexed 1L therapy, n (%) | |||
| Dupilumab | 460 (98.7) | 7,552 (99.4) | 8,012 (99.4) |
| Tralokinumab | 0 | 0 | 0 |
| Abrocitinib | 3 (0.6) | 10 (0.1) | 13 (0.2) |
| Upadacitinib | 3 (0.6) | 35 (0.5) | 38 (0.5) |
| Prior AD-related therapies, n (%) | |||
| Topical therapiesa | 258 (55.4) | 3,405 (44.8) | 3,663 (45.4) |
| Immunosuppressantsb | 0 | 0 | 0 |
| Systemic corticosteroids | 167 (35.8) | 2,134 (28.1) | 2,301 (28.5) |
| Phototherapy | 15 (3.2) | 140 (1.8) | 155 (1.9) |
| Baseline total cost ($USD), mean (SD) | 31,379 (46,465) | 29,483 (31,546) | 29,593 (32,593) |
a
Topical corticosteroids, calcineurin inhibitors, PDE-4 inhibitors, JAK inhibitor.
b
Methotrexate, azathioprine, cyclosporine, mycophenolate mofetil.
1L = first line; AD = atopic dermatitis; CCI = Charlson Comorbidity Index;
CDHP = consumer-driven health plan; EPO = exclusive provider organization; HDHP = high-deductible health plan; HMO = health maintenance organization; JAK = Janus kinase; POS = point-of-service plan; PPO = preferred provider organization; USD = US dollars.